Gooding, Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes
Cell Metab 8:2637 Dzhura I, Chepurny OG, Kelley GG, Leech CA, Roe MW, Dzhura E, Afshri P, Malik S, Rindler MJ, Xu X, Lu Y, Smrcka AV, Holz GG (2010) Epac2-dependent mobilization of intracellular Ca 2+ by glucagon-like peptide-1 receptor agonist exendin-4 is disrupted in -cells of phospholipase C knockout mice
239 reported that ER stress is a downstream pathological consequence of impaired autophagy during AP
Its not about a quick fix
Warnings Not for Human or Veterinary Use: This product is strictly for in vitro and animal research purposes only
Injectable GHK-Cu protocols typically use 1-2 mg daily subcutaneously, with visible results appearing at 12-16 weeks and optimal outcomes at 6+ months